ORAL VT-464 IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ENZALUTAMIDE, ANDROGEN RECEPTOR POSITIVE TRIPLE-NEGATIVE BREAST CANCER PATIENTS, AND MEN WITH ER POSITIVE BREAST CANCER: